The FDA's drug database lists a supplement, dated 26 October, to an abbreviated new drug application for generic voriconazole from Meitheal. A supplement to an ANDA usually covers manufacturing, labelling or packaging changes; the record does not state the content.
This is an administrative action rather than a safety finding or a new indication. It does not change how voriconazole is used.
- This is a supplement to an existing generic approval, not a new indication
- No safety concern is stated in the record
- Prescribing and monitoring of voriconazole are unchanged
- Generic availability in India is separate from this US action
Why it matters
Regulatory activity is not always clinical news, and this one is not.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free